Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Hengrui Pharma Announces Strong 2025 Annual Results

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline